Clinical Trial Update: Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer [Phase 1, Phase 2]

View source ↗

Summary

The recombinant NAPc2 safety study for metastatic colon cancer (Phase 1/Phase 2) has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• NAPc2 (NAPc2)

Snippet

Sponsor: ARCA Biopharma, Inc. | Conditions: Colon Cancer | Phase 1, Phase 2 | Status: SUSPENDED